VIVA (vinorelbine, ifosfamide, vincristine, actinomycin‐D): A new regimen in the armamentarium of systemic therapy for high‐risk rhabdomyosarcoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

VIVA (vinorelbine, ifosfamide, vincristine, actinomycin‐D): A new regimen in the armamentarium of systemic therapy for high‐risk rhabdomyosarcoma

Published:2020-09-07 Issue:11 Volume:67 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Ferrari Andrea¹^ORCID,Chiaravalli Stefano¹,Zecca Marco²^ORCID,Recupero Santina²,Pascale Silvia³,Bergamaschi Luca¹^ORCID,Casanova Michela¹

Affiliation:

1. Pediatric Oncology Unit Fondazione IRCCS Istituto Nazionale Tumori Milan Italy

2. Department of Pediatric Hematology and Oncology Fondazione IRCCS Policlinico San Matteo Pavia Italy

3. Pediatric Hematology and Oncology Unit, Hematology‐Oncology Department Santo Spirito Hospital Pescara Pescara Italy

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.28649

Reference13 articles.

1. Rhabdomyosarcoma

2. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

3. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

4. 10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers

5. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatic rhabdomyosarcoma: Evidence of the impact of radiotherapy on survival. A retrospective single‐center experience;Pediatric Blood & Cancer;2022-06-30

2. Antineoplastics;Reactions Weekly;2020-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3